Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare ConferenceBusiness Wire · 4 days ago
Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial UpdateBusiness Wire · 5 days ago
Down 22% in 4 Weeks, Here's Why Innate Pharma (IPHA) Looks Ripe for a TurnaroundZacks Investment Research · Oct 8, 2026
Down 25% in 4 Weeks, Here's Why You Should You Buy the Dip in Innate Pharma (IPHA)Zacks Investment Research · Oct 5, 2026
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Stock Has Average Target Price of $6.67Defense World · Sep 30, 2026
Innate Pharma (IPHA) Upgraded to Buy: Here's What You Should KnowZacks Investment Research · Sep 23, 2026Innate Pharma S.A. is a biotechnology firm, founded in 1999 and headquartered in Marseille, France, that specializes in the discovery, development, and market introduction of therapeutic antibodies. The company primarily targets oncology indications across France and internationally, with some programs also addressing inflammatory diseases and viral infections. Its clinical-stage pipeline features several key assets: Lacutamab (IPH4102): An anti-KIR3DL2 antibody undergoing Phase II trials for cutaneous T-cell and peripheral T-cell lymphoma, and also for refractory Sézary syndrome.
| Date | Est. | Actual | |
|---|---|---|---|
| Sep 17, 2026 | -$0.29 | -$0.24 | Beat |
| May 13, 2026 | -$0.35 | -$0.35 | Beat |
| Nov 13, 2025 | -$0.33 | -$0.30 | Beat |
| May 13, 2025 | -$0.27 | -$0.35 | Miss |
| Nov 13, 2024 | -$0.30 | -$0.34 | Miss |
| May 14, 2024 | -$0.44 | -$0.13 | Beat |